Press and media
Press releases
More regular updates and key information, updates and news can be found through our tweets
CellCentric presents early haem clinical data at ASH
CellCentric to present haem clinical data at ASH
CellCentric strengthens leadership team
Latest tweets from @CellCentric
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
Karen and Debbie are in Rio for #IMS24. Our novel oral drug for R/R multiple myeloma is in Phase II trials. #MMSM #multiplemyeloma
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!